Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Asahi Kasei Corp    3407   JP3111200006

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Asahi Kasei Corp. : Construction of new acetonitrile plant in Korea

share with twitter share with LinkedIn share with facebook
share via e-mail
03/06/2012 | 04:35am CET

Asahi Kasei Chemicals Corp.

Asahi Kasei Chemicals has finalized a decision to construct a new acetonitrile plant in Korea. The plant will have a production capacity of 11,000 tons per year, and start-up is scheduled for January 2014. Having a second production base for acetonitrile, in addition to its Japanese base, will enable Asahi Kasei Chemicals to assure a reliable supply of acetonitrile as demand continues to grow rapidly worldwide.

Acetonitrile is produced by refining the crude acetonitrile obtained as a byproduct of acrylonitrile (AN). It is mainly used as a solvent in the manufacture of pharmaceuticals, with other notable uses including as analytical reagent and in the field of agrichemicals. With an acetonitrile plant in Kawasaki, Kanagawa, Japan, having a production capacity of 14,000 tons per year, Asahi Kasei Chemicals is a major supplier to markets in Asia and Europe as well as Japan. Strong growth in demand for acetonitrile is forecasted, particularly for use in the field of pharmaceutical manufacture. Asahi Kasei Chemicals had therefore been examining how best to increase production capacity and ensure reliable supply as markets continue to grow.

A decision was made to construct a new acetonitrile plant at Tong Suh Petrochemical Corp., Ltd., an Asahi Kasei Group company in Korea, which is currently constructing a new AN plant in Ulsan with startup scheduled for January 2013. The acetonitrile plant in Korea will utilize crude acetonitrile byproduct from the AN plants in Korea.

Having two production bases for acetonitrile, in Japan and Korea, will enable Asahi Kasei Chemicals to provide reliable supply to meet growing demand in the pharmaceutical industry especially in India and China.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASAHI KASEI CORP
11/21 ASAHI KASEI : New Findings in Life Science Research Described from Asahi Kasei P..
11/21 ASAHI KASEI : Study Findings from Asahi Kasei Pharma Corporation Provide New Ins..
11/16 ASAHI KASEI : Patent Issued for Method for Producing Parvovirus Having High Infe..
11/14 ASAHI KASEI : Europe participates in European multi-partner project on CCUS tech..
11/09 ASAHI KASEI : Home Order Trends – October 2017
11/07 ASAHI KASEI : Notice of payment of dividends from surplus (interim dividend) and..
11/02 DATA STORAGE : Researchers Submit Patent Application, "Patient Data Hub", for Ap..
11/02 ASAHI KASEI : MILITARY $48,442 Federal Contract Awarded to Zoll Medical
11/02 New Foldable ZTE M Z-01K from NTT DOCOMO uses Audio DSP CODEC AK4962
11/01 ASAHI KASEI : Engineering to demonstrate predictive detection of signs of abnorm..
More news
News from SeekingAlpha
11/07 Asahi Kasei Corp. ADR 2017 Q2 - Results - Earnings Call Slides
01/19 Evotec collaborates with Japan's Asahi Kasei Pharma on drug discovery
2016 JAPANESE EQUITIES : False Dawn Or Rising Star?
2016 GMO International Active EAFE Strategy Q3 2016 Commentary
2016 A YEAR OF SCANDAL : The Beginning Of The End Of Cronyism In Japan?
Financials ( JPY)
Sales 2018 1 982 B
EBIT 2018 -
Net income 2018 129 B
Debt 2018 179 B
Yield 2018 1,81%
P/E ratio 2018 15,28
P/E ratio 2019 14,97
EV / Sales 2018 1,09x
EV / Sales 2019 1,02x
Capitalization 1 976 B
Duration : Period :
Asahi Kasei Corp Technical Analysis Chart | 3407 | JP3111200006 | 4-Traders
Technical analysis trends ASAHI KASEI CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Average target price 1 359  JPY
Spread / Average Target -3,6%
EPS Revisions
Hideki Kobori President & Representative Director
Ichiro Itoh Chairman
Norio Ichino Independent Director
Masafumi Nakao Director
Yuji Kobayashi Representative Director
Sector and Competitors
1st jan.Capitalization (M$)
ASAHI KASEI CORP36.49%17 628
AIR LIQUIDE9.68%53 953
PRAXAIR, INC.28.54%43 332
GIVAUDAN21.60%21 295